Introduction to Pharmaceutical Pricing and Market Access

Chloe: Welcome to the London School of Business and Administration podcast—where breakthrough ideas meet real-world impact. I'm Chloe, and today we're diving into Introduction to Pharmaceutical Pricing and Market Access—the one concept that quietly shapes everything from boardroom decisions to your daily workflow. Chloe: Have you ever wondered why a life‑saving drug you hear about on the news can cost $5,000 in one country and just $50 in another? Rohan: That's a great question, Chloe, and it gets to the heart of pricing strategy, regulation, and market dynamics—all of which have evolved dramatically over the past two decades. Imani: I actually saw this play out last quarter when my company launched a biosimilar in Europe and then tried to enter a South American market. The price points were worlds apart, and the reasons were far more than just currency exchange. Chloe: Fascinating. Rohan, can you walk us through the historical shift that turned pricing from a back‑office task into a strategic pillar? Rohan: Absolutely. In the early 2000s, most pharma firms used cost‑plus pricing—add a margin to manufacturing costs. But as health systems started demanding value for money, we saw the rise of health technology assessments, reference pricing, and outcome‑based contracts. Those tools forced companies to think about price as a function of clinical benefit, patient access, and payer willingness to pay. Imani: And that shift hit us hard. We initially priced our product based on R&D spend, assuming the market would follow. Within weeks, we faced pushback from payers who demanded evidence of cost‑effectiveness. We had to renegotiate and, frankly, we learned the hard way that data drives price. Chloe: So data is the new currency. What kind of data should teams be gathering from day one? Rohan: Start with epidemiology—how many patients could benefit? Then layer in real‑world evidence: adherence rates, quality‑of‑life metrics, and downstream cost savings. The more robust your value dossier, the stronger your negotiation position. Imani: I remember we missed an early opportunity to collect real‑world adherence data because we were focused on launch timelines. When the payer asked for it later, we scrambled, and it delayed reimbursement by six months. Lesson learned: integrate market access considerations into the development plan from the get‑go. Chloe: That sounds like a classic pitfall—treating pricing as an afterthought. How can teams avoid that trap? Rohan: Embed a market access lead in the cross‑functional team right after IND filing. That person can map the regulatory landscape, identify pricing pathways, and set milestones for evidence generation. Imani: In practice, we instituted weekly check‑ins between our medical affairs, health economics, and commercial teams. It forced us to align on what data we needed and when, turning a reactive process into a proactive one. Chloe: It’s amazing how a simple routine can change outcomes. Rohan, could you share a framework that listeners can start using today? Rohan: Sure. Think of the "3‑P" framework: Product value, Payer landscape, and Pricing mechanisms. First, quantify the product's clinical and economic value. Second, map payer policies—reference pricing, formularies, HTA criteria. Third, choose the right pricing model—tiered pricing, risk‑sharing, or value‑based agreements. Apply this loop iteratively as new data emerges. Imani: I used that exact framework when we re‑priced a cardiology drug for a middle‑income market. By aligning the product’s proven reduction in hospital readmissions with a risk‑sharing contract, we secured a 20% price uplift while improving patient access. Chloe: That’s a win‑win. Before we wrap, what’s one piece of advice you’d give to someone just starting in pharmaceutical pricing? Rohan: Never assume that price is static. Treat it as a hypothesis you test continuously with data, stakeholder feedback, and market signals. Imani: And be humble enough to learn from mistakes early. A misstep in pricing can cost months of market delay, but it also offers priceless insights for the next launch. Chloe: Thank you both for those powerful takeaways. If this resonated, share it with one person who needs to hear it—and hit subscribe so you never miss an episode that moves you forward. Until next time, keep turning insight into impact.